ReviewPharmaceutical science advances2026
Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.
Review in Pharmaceutical science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From inhibition to degradation: advances in highly selective targeting strategies for HPK1.Molecular diversity · 2026Review
- Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells represent a critical component of the innate immune system, capable of exerting potent cytotoxic activity against infected and transformed cells. However, tumor cells evolve diverse strategies to evade NK cell-mediated surveillance, including modulation of receptor-ligand interactions, secretion of immunosuppressive cytokines, metabolic disruption, and induction of NK cell exhaustion. In this review, we summarise the mechanisms by which tumors escape NK cell control and highlight recent advances in NK cell-based immunotherapies, including adoptive NK transfer, immune checkpoint blockade, and CAR-engineered NK cells. Ongoing efforts to improve NK cell persistence, infiltration, and functional resilience hold promise for optimising clinical efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.